Search - tctmd.com

Displaying 1 - 20 of 101

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Daily News

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Yael L. Maxwell

October 23, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

News Daily News

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

Todd Neale

November 22, 2023

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Daily News

Statin Therapy Still Lacking for Many US Patients With ASCVD

L.A. McKeown

August 07, 2023

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

News Conference News EAS 2023

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

Michael O'Riordan

May 26, 2023

Advertisement

Year in Review: Top Prevention Stories of 2025

Risk Calculators Miss Many Patients Who Present With First MI

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Statins Are Cost-effective in the Elderly

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Statin Therapy Still Lacking for Many US Patients With ASCVD

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content